Skip to main content
SleepCited

Melatonin for primary insomnia?

Review Drug and therapeutics bulletin 2009
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D19567841'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Type d'étude
Review
Population
None
Intervention
Melatonin for primary insomnia? None
Comparateur
None
Critère de jugement principal
Melatonin for primary insomnia?
Direction de l'effet
Mixed
Risque de biais
Unclear

Abstract

Melatonin, a hormone produced by the pineal gland, has a key role in regulating circadian rhythms, most importantly, the sleep-wake cycle. Melatonin's action has led to its being tried as a treatment for a wide range of sleep disorders, such as jet lag, primary insomnia, sleep-wake cycle disruption and sleep problems in children with neuro-developmental disorders. Until recently, it had not been licensed in the UK for any indication. Prolonged-release melatonin (Circadin - Lundbeck) has now been licensed as a treatment for primary insomnia. Here we consider whether this product has a place in the management of people with this condition.

En bref

Prolonged-release melatonin (▼Circadin – Lundbeck) has now been licensed as a treatment for primary insomnia and it is considered whether this product has a place in the management of people with this condition.

Used In Evidence Reviews

Similar Papers